Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
for Non-Small Cell Lung Cancer
Drug: Ivonescimab
89 locations incl. Chandler
Sponsor: Summit Therapeutics
Sex: All·Age: 18+
Code: NCT06767514·Phase 3·Recruiting